-
Do you want to know how reliable your data are?
PAASP is a global leader in the assessment and accreditation of nonclinical research practice in the field of life sciences. We provide services to facilitate the generation of robust and reliable data and enable improved and accelerated decision-making. Our mission is to increase the probability that basic nonclinical discoveries will translate into safe and effective clinical treatments.
PAASPort®
A tool to judge risk of bias in biomedical research
Identify potential sources of bias early and improve decision-making.
START YOUR JOURNEY TO ACCREDITATION
by getting detailed information about PAASPort®
Risks in early-stage biotech investment
As the recent cases illustrate, apparent or actual issues with data integrity and research rigor can damage not only reputation of individual scientists but also affect the value of companies, whether privately held or publicly traded.
PAASP introduces a new service for the investment community engaged in early-stage biotech:
PAASPort®-based assessment of investment opportunities for data integrity and research rigor risks.
PAASP NETWORK PARTNERS ARE SUPPORTED BY
Funder of EQIPD from the Innovative Medicines Initiative 2 Joint Undertaking.
Conferrer of the NIDA Challenge Award and SBIR Grant for PAASPort®.
United States sponsor of the Global Preclinical Data Forum and sponsor of the Negative Data Prize and PEERS project.
PARTNER ORGANIZATIONS
A taste of our most recent headlines.
2024 Best Negative Data Prize in Preclinical Neuroscience
April 5, 2024The Global Preclinical Data Forum, in collaboration with Cohen Veterans Bioscience, the Partnership for Assessment and Accreditation of Scientific Practice (PAASP)…
Read MoreDon’t throw the baby out with the bathwater
December 22, 2023The pressure to replace animal research with non-animal methods is growing. Earlier this year, NIH has issued a “Request for Information…
Read More“Home inspections” for life sciences companies going public before clinical proof of concept
December 22, 2023For over a decade, there is a trend of less specialized investment firms and public equity investors betting on life sciences…
Read More